Cxbladder® Triage
Urine genomic test to risk-stratify haematuria — AUA Guideline Level A Evidence
Cxbladder® Triage is a non-invasive urine genomic test that measures the expression of five biomarker genes (CDC2, IGFBP5, HOXA13, MDK, CXCR2) to determine the likelihood of urothelial cancer. It is recommended in the 2020 American Urological Association (AUA) Microhaematuria Guideline as the first and only urine-based genomic biomarker test supported by Level A Evidence. Cxbladder® Triage Plus is an improved version of the test, which also includes 6 DNA SNVs from 2 genes (FGFR3/TERT)
Patients presenting to urologic care with haematuria (visible or non-visible) requiring risk stratification to guide the need for cystoscopy. Suitable for use in primary care and urology settings to de-intensify work-up in low-risk patients.
Not for patients with active urinary tract infection. Not a replacement for cystoscopy in high-risk patients. Not intended for population-level asymptomatic screening.
| Step / Test | Accuracy | Notes |
|---|---|---|
| Sensitivity | 94% | |
| Specificity | 98% |
Urine in Cxbladder container
30–50 mL midstream urine collected into the Cxbladder collection tube (contains preservative). Do not use catheter samples.
- First void urine (Only 2nd pass of the day or later is accepted)
- Grossly bloody urine
- Acute UTI (Treat UTI first and delay test for 2 weeks)
- <2 weeks after cystoscopy
- <6 weeks after BCG
Available through Codex Genetics as the authorised Pacific Edge distributor in Hong Kong. Please contact us for test kits, collection instructions, and ordering.
Cxbladder specimens must be collected using the dedicated Cxbladder collection kit.
- Request a collection kit from your healthcare provider or Codex Genetics.
- Collect midstream urine (30–50 mL) into the provided tube with preservative.
- Seal securely; store at room temperature.
- Deliver to Codex Genetics Laboratory within 5 days of collection. Address: Unit 220, 2/F, Building 16W, HKSTP, Pak Shek Kok, NT, Hong Kong.
Please contact us for pricing.
- Cxbladder Triage Score < 4.0
- Low probability of urothelial carcinoma
- Cxbladder Monitor Score >= 4.0
- Cannot rule out urothelial carcinoma and continue with the clinician-directed standard clinical workup to establish if Urothelial Carcinoma is present
Bladder cancer is the 10th most common cancer globally. Haematuria is the most common presenting symptom, but most patients with haematuria do not have bladder cancer. The AUA 2020 Microhaematuria Guideline recommends Cxbladder Triage as a Level A Evidence urine biomarker test to risk-stratify patients and reduce unnecessary invasive investigations. The test analyses gene expression of IGFBP5, HOXA13, MDK, CDC2, and CXCR2.
Hong Kong-based molecular diagnostics laboratory specialising in clinical genomics, precision oncology, and rare disease diagnosis. Accredited to ISO 27001 and GenQA standards.
© 2026 Codex Genetics Limited. All rights reserved.
